Theravance Biopharma, Inc. announced that Independent Director, Bill Young, will not be standing for reelection to the Board of Directors at the company's 2023 Annual General Meeting for shareholders.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.92 USD | -1.98% | -5.01% | -20.64% |
05-13 | Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours | MT |
05-13 | Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.64% | 443M | |
+37.80% | 705B | |
+32.82% | 583B | |
-3.69% | 364B | |
+20.18% | 332B | |
+4.90% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.81% | 169B |
- Stock Market
- Equities
- TBPH Stock
- News Theravance Biopharma, Inc.
- Theravance Biopharma, Inc. Announces Independent Director, Bill Young, Will Not Be Standing for Reelection to the Board of Directors